# NCT03933735 (NCT03933735)

> A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03933735
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Multiple Myeloma
- Interventions: TNB-383B
- Enrollment: 220
- Primary outcome: Number of Participants with Dose-limiting toxicities (DLT)
- Primary outcome: Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
- Primary outcome: Maximum Observed Plasma Concentration of TNB-383B (Cmax)
- Primary outcome: Time to Cmax of TNB-383B (Tmax)
- Primary outcome: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast)
- Primary outcome: Clearance (CL) of TNB-383B
- Primary outcome: Terminal Phase Elimination Rate Constant (Beta) of TNB-383B
- Primary outcome: Terminal Half-Life (t1/2) of TNB-383B
- Primary outcome: Number of Participants with of Anti-drug Antibody (ADA)

## Indexed commentary on NCT03933735 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03933735